Results for this period
Third quarter1 January 2026–30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Demand remained firm for medical-device CDMO services in the Medical segment and decorative finishing in the Industrial Materials segment, while demand for tablets in the Devices segment declined substantially. In addition to the impairment loss on goodwill related to USM, production-related costs for exterior functional parts for mobility applications in the Industrial Materials segment increased.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥144,980 million (YoY -0.2%) |
| Operating profit | ¥-3,679 million |
| Ordinary income | ¥-4,730 million |
| Profit attributable to owners of the parent | ¥-5,773 million |
| Net income per share | −¥121.74 |
| Equity ratio | End of the current fiscal period 45.4 / End of previous period 46.1 |
| Total assets | ¥243,330 million |
| Net assets | ¥112,090 million |
| Cash flows from operating activities | ¥8,494 million |
| Cash flows from investing activities | ¥-14,095 million |
| Cash flows from financing activities | ¥-6,627 million |
| Cash and cash equivalents at end of period | ¥27,591 million |
| Full-year earnings forecast | Net Sales ¥195,000 million (YoY +0.1%) / Operating profit ¥-3,300 million / Ordinary income ¥-12,200 million / Net income ¥-14,000 million |
| Revision to Earnings Forecast | Not disclosed → Net Sales ¥195,000 million / Operating profit ¥-3,300 million / Ordinary income ¥-12,200 million / Net income ¥-14,000 million |
| Annual Dividend Forecast | ¥50 → ¥50（0.0%） |
| Segment revenue | Medical ¥43,932 million (YoY +9.5%), Industrial Materials ¥62,987 million (YoY +10.4%), Devices ¥33,845 million (YoY -22.8%) |
| Segment profit | Medical ¥2,996 million (YoY +21.3%), Industrial Materials ¥2,278 million (YoY -23.9%), Devices ¥-5,565 million |
| Depreciation and amortization | ¥7,929 million |
| Impairment loss | ¥6,759 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 1 / Company name USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY / Excluded Number of companies 1 / Company name USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors) |
| Issued Shares at Period-End | 48,016,100 Shares |
| Treasury Shares at Period-End | 542,652 Shares |
| Factors Behind Changes in Business Performance | Demand remained firm for medical-device CDMO services in the Medical segment and decorative finishing in the Industrial Materials segment, while demand for tablets in the Devices segment declined substantially. In addition to the impairment loss on goodwill related to USM, production-related costs for exterior functional parts for mobility applications in the Industrial Materials segment increased. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.A substantial decline in demand for tablets, a ¥6.759 billion impairment loss on goodwill related to USM, and higher production-related costs for exterior functional parts for mobility applications in the Industrial Materials segment weighed on profit. The recognition of financial expenses associated with a change in the agreement among holders of interests in a sub-subsidiary was cited as the reason for revising the full-year forecast.